To provide a new vector and viral vector, expressing a gene i.e., an exogenous nucleic acid sequence in objective target cells (e.g. T-cells, bone marrow cells, epithelial cells, hepatocytes, etc.).
As the nucleic acid component of the vector, 1 natural promotor/enhancer region having a modified sequence segment, a gene or gene segment of 1 non-natural promotor/enhancer or a non-natural promotor, and a natural virus terminator, or a processing signal or its segment are included. The viral vector comprises the virus or a viral portion, having an adsorption component on its surface or envelope, wherein, one is for a packaging cell line and the other is for delivery to a target cell. The new method for propagating the vector or viral vector is also provided.
RABBANI ELAZAR
NG JEFFERY
LUBARSKY LEV
JPN4007002724, Ｈｕｍ． Ｇｅｎｅ Ｔｈｅｒ．, 1995, Ｖｏｌ．６， Ｎｏ．６, ７３３−７４２, US
JPN4007002725, Ｇｅｎｅ, 1994, Ｖｏｌ．１４４， Ｎｏ．２, ２３７−２４１, US
JPN6010034517, ＹＵ， Ｓ．Ｆ． ｅｔ ａｌ．, "”Ｓｅｌｆ−ｉｎａｃｔｉｖａｔｉｎｇ ｒｅｔｒｏｖｉｒａｌ ｖｅｃｔｏｒｓ ｄｅｓｉｇｎｅｄ ｆｏｒ ｔｒａｎｓｆｅｒ ｏｆ ｗｈｏｌｅ ｇｅｎｅｓ ｉｎｔｏ ｍａｍｍａｌｉａｎ ｃｅｌｌｓ．”", ＰＲＯＣ． ＮＡＴＬ． ＡＣＡＤ． ＳＣＩ． ＵＳＡ, 198605, Ｖｏｌ．８３， Ｎｏ．１０, Ｐ．３７９４−３１９８
JPN6010034519, ＹＥＥ， Ｊ．Ｋ． ｅｔ ａｌ．, "”Ｇｅｎｅ ｅｘｐｒｅｓｓｉｏｎ ｆｒｏｍ ｔｒａｎｓｃｒｉｐｔｉｏｎａｌｌｙ ｄｉｓａｂｌｅｄ ｒｅｔｒｏｖｉｒａｌ ｖｅｃｔｏｒｓ．”", ＰＲＯＣ． ＮＡＴＬ． ＡＣＡＤ． ＳＣＩ． ＵＳＡ, 198708, Ｖｏｌ．８４， Ｎｏ．１５, Ｐ．５１９７−５２０１
JPN6010034520, ＤＯＵＧＨＥＲＴＹ， Ｊ．Ｐ． ｅｔ ａｌ．, "”Ａ ｐｒｏｍｏｔｅｒｌｅｓｓ ｒｅｔｒｏｖｉｒａｌ ｖｅｃｔｏｒ ｉｎｄｉｃａｔｅｓ ｔｈａｔ ｔｈｅｒｅ ａｒｅ ｓｅｑｕｅｎｃｅｓ ｉｎ Ｕ３ ｒｅｑｕｉｒｅｄ ｆｏｒ ３’ ＲＮＡ ｐｒｏｃｅ", ＰＲＯＣ． ＮＡＴＬ． ＡＣＡＤ． ＳＣＩ． ＵＳＡ, 198703, Ｖｏｌ．８４， Ｎｏ．５, Ｐ．１１９７−１２０１
Next Patent: POSITIVE SELECTION BASED ON MANNOSE OR XYLOSE